Contact
searchSearch
HMP Global

News

News
Oncology Biosimilars Offer Cost-Efficient Solutions for Sustainable Health Care
12/19/2024
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have...
12/19/2024
First Report Managed Care
News
Global Oncology Biosimilars Market to Surge to $35.79 Billion by 2034
12/19/2024
The global oncology biosimilars market is set to experience remarkable growth, with its value projected to soar from $6.50 billion in 2024 to $35.79 billion by 2034, at an impressive CAGR of 18.6%.
The global oncology biosimilars market is set to experience remarkable growth, with its value projected to soar from $6.50 billion in 2024 to $35.79 billion by 2034, at an impressive CAGR of 18.6%.
The global oncology biosimilars...
12/19/2024
First Report Managed Care
News
Study Suggests Innovative Value-Based Models for Expanding Cell and Gene Therapy Access
12/17/2024
Cell and gene therapies (CGTs) offer groundbreaking approaches for treating rare and complex conditions. However, the high costs of CGTs create barriers to equitable access and affordability. A study published in Journal of Medical Economics...
Cell and gene therapies (CGTs) offer groundbreaking approaches for treating rare and complex conditions. However, the high costs of CGTs create barriers to equitable access and affordability. A study published in Journal of Medical Economics...
Cell and gene therapies (CGTs)...
12/17/2024
First Report Managed Care
News
Effectiveness of SARS-CoV-2 Vaccination Among Health Care Workers
12/17/2024
A comprehensive analysis of SARS-CoV-2 vaccination in health care workers shows high levels of protection against infection, symptomatic infection, and hospitalization with evidence of waning immunity over time.
A comprehensive analysis of SARS-CoV-2 vaccination in health care workers shows high levels of protection against infection, symptomatic infection, and hospitalization with evidence of waning immunity over time.
A comprehensive analysis of...
12/17/2024
First Report Managed Care
News
Adding Selexipag to Standard Therapy Reduces Hospitalizations in Patients With Pulmonary Arterial Hypertension
12/16/2024
Adding oral selexipag to double oral therapy (DOT) within 6 months significantly reduces the risk of hospitalization and disease progression in patients with pulmonary arterial hypertension (PAH).
Adding oral selexipag to double oral therapy (DOT) within 6 months significantly reduces the risk of hospitalization and disease progression in patients with pulmonary arterial hypertension (PAH).
Adding oral selexipag to double...
12/16/2024
First Report Managed Care
News
Evaluating AI’s Role in Mortality Prediction for Patients With Severe COVID-19
12/13/2024
A large subset of patients with COVID-19 develop severe complications, necessitating advanced interventions and contributes to high mortality rates. Artificial intelligence (AI) has shown promise in predicting severe disease, but its efficacy...
A large subset of patients with COVID-19 develop severe complications, necessitating advanced interventions and contributes to high mortality rates. Artificial intelligence (AI) has shown promise in predicting severe disease, but its efficacy...
A large subset of patients with...
12/13/2024
First Report Managed Care
News
Meta-Analysis Finds More Arterial Stiffness in Patients With MS
12/13/2024
Patients with multiple sclerosis (MS) have significantly worse vascular function, particularly greater arterial stiffness, compared with healthy controls.
Patients with multiple sclerosis (MS) have significantly worse vascular function, particularly greater arterial stiffness, compared with healthy controls.
Patients with multiple sclerosis...
12/13/2024
First Report Managed Care
News
Biosimilar Competition May Fail to Lower Out-of-Pocket Costs for Patients
12/13/2024
Despite the promise of cost savings with biosimilar competition, a study published in JAMA Network found that patient spending on biologic drugs remained the same, indicating the need for policy interventions to ensure affordability.
Despite the promise of cost savings with biosimilar competition, a study published in JAMA Network found that patient spending on biologic drugs remained the same, indicating the need for policy interventions to ensure affordability.
Despite the promise of cost...
12/13/2024
First Report Managed Care
News
Overcoming Barriers in CAR-T Therapy Through Precision Gene Editing
12/13/2024
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a revolutionary approach to treating B-cell malignancies such as CD19+ cancers. However, their application has been limited by challenges such as high costs, safety concerns with...
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a revolutionary approach to treating B-cell malignancies such as CD19+ cancers. However, their application has been limited by challenges such as high costs, safety concerns with...
Chimeric antigen receptor T-cell...
12/13/2024
First Report Managed Care
News
Machine Learning Advances Revolutionize Pulmonary Arterial Hypertension Diagnosis
12/09/2024
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such as combining machine learning with echocardiography and electrocardiography (ECG), show promising results in diagnosing pulmonary arterial hypertension (PAH), offering a potential noninvasive alternative to...
Machine learning techniques such...
12/09/2024
First Report Managed Care

Behind the Bill

Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations 2.0: New Administration, Same Mission?
01/22/2025
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major...
01/22/2025
First Report Managed Care
Behind the Bill
The First 100 Days: Health Care's Critical Deadlines in 2025
01/15/2025
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces...
01/15/2025
First Report Managed Care
Behind the Bill
Trump's Executive Orders in a Post-Chevron World: Implications for Health Care Policy
01/08/2025
Happy New Year! As we dive into 2025, it’s clear that this year promises to bring significant changes to health care. With President-elect Donald Trump's inauguration just weeks away, the spotlight is already shifting to how his...
Happy New Year! As we dive into 2025, it’s clear that this year promises to bring significant changes to health care. With President-elect Donald Trump's inauguration just weeks away, the spotlight is already shifting to how his...
Happy New Year! As we dive into...
01/08/2025
First Report Managed Care
Behind the Bill
A Tale of Two Congresses—Health Care Policy in the 117th vs 118th
12/18/2024
The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor's transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the...
The 118th Congress is wrapping up with a whimper rather than a bang when it comes to health care legislation, particularly compared to its predecessor's transformative impact on pharmaceutical policy. As we reflect on these past 4 years, the...
The 118th Congress is wrapping...
12/18/2024
First Report Managed Care
Behind the Bill
Medicare Privatization Under New CMS Leadership: What's Really at Stake
12/11/2024
After writing about Dr Oz's potential impact on Medicare drug negotiations last week, I found myself diving deeper into an aspect of his nomination that deserves closer attention: his vision for Medicare's future. A letter from Senate...
After writing about Dr Oz's potential impact on Medicare drug negotiations last week, I found myself diving deeper into an aspect of his nomination that deserves closer attention: his vision for Medicare's future. A letter from Senate...
After writing about Dr Oz's...
12/11/2024
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations Under New CMS Leadership
12/04/2024
President-elect Donald Trump nominated Dr Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS). With this potential change in leadership, are there any implications for Medicare’s drug price negotiation program,...
President-elect Donald Trump nominated Dr Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS). With this potential change in leadership, are there any implications for Medicare’s drug price negotiation program,...
President-elect Donald Trump...
12/04/2024
First Report Managed Care
Behind the Bill

When Recess Isn’t a Break: What NLRB v Canning Means for HHS
11/20/2024
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s...
As Robert F. Kennedy Jr’s nomination for Secretary of Health and Human Services (HHS) moves through the Senate, there’s growing discussion about whether a recess appointment could be used to bypass confirmation challenges. The Supreme Court’s...
As Robert F. Kennedy Jr’s...
11/20/2024
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use